Acute bronchitis is one of the most common diseases. About 5% of adults are affected and about 6% of children have at least one episode a year. In 2010, COPD affects 329 million people or nearly 5% of the global population. In 2013, it resulted in 2.9 million deaths up from 2.4 million deaths in 1990.
Prevention is by not smoking and avoiding other lung irritants. Frequent hand washing may also be protective. Treatment of acute bronchitis typically involves rest, paracetamol (acetaminophen), and NSAIDs to help with the fever.Cough medicine has little support for its use and is not recommended in children less than six years of age. There is tentative evidence that salbutamol may be useful in those with wheezing; however, it may result in nervousness.[needs update]Antibiotics should generally not be used. An exception is when acute bronchitis is due to pertussis. Tentative evidence supports honey and pelargonium to help with symptoms.
Acute bronchitis is one of the most common diseases. About 5% of adults are affected and about 6% of children have at least one episode a year. It occurs more often in the winter. More than 10 million people in the United States visit a doctor each year for this condition with about 70% receiving antibiotics which are mostly not needed. There are efforts to decrease the use of antibiotics in acute bronchitis.
Chronic bronchitis is defined as a productive cough that lasts for three months or more per year for at least two years. Most people with chronic bronchitis have chronic obstructive pulmonary disease (COPD). Protracted bacterial bronchitis is defined as a chronic productive cough with a positive bronchoalveolar lavage that resolves with antibiotics. Symptoms of chronic bronchitis may include wheezing and shortness of breath, especially upon exertion and low oxygen saturations. The cough is often worse soon after awakening and the sputum produced may have a yellow or green color and may be streaked with specks of blood.
Individuals with an obstructive pulmonary disorder such as bronchitis may present with a decreased FEV1 and FEV1/FVC ratio on pulmonary function tests. Unlike other common obstructive disorders such as asthma or emphysema, bronchitis rarely causes a high residual volume (the volume of air remaining in the lungs after a maximal exhalation effort).
^ abVestbo, Jørgen (2013). "Diagnosis and Assessment"(PDF). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease. pp. 9–17.
^ abReilly, John J.; Silverman, Edwin K.; Shapiro, Steven D. (2011). "Chronic Obstructive Pulmonary Disease". In Longo, Dan; Fauci, Anthony; Kasper, Dennis; Hauser, Stephen; Jameson, J.; Loscalzo, Joseph. Harrison's Principles of Internal Medicine (18th ed.). McGraw Hill. pp. 2151–9. ISBN978-0-07-174889-6.
^Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, et al. (December 2012). "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet380 (9859): 2163–96. doi:10.1016/S0140-6736(12)61729-2. PMID23245607.
^Smith, SM; Schroeder, K; Fahey, T (24 November 2014). "Over-the-counter (OTC) medications for acute cough in children and adults in community settings.". The Cochrane database of systematic reviews11: CD001831. doi:10.1002/14651858.CD001831.pub5. PMID25420096.
^Willemse, BW; Postma, DS; Timens, W; ten Hacken, NH (March 2004). "The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation". The European Respiratory Journal23 (3): 464–476. doi:10.1183/09031936.04.00012704. PMID15065840.
^Mohamed Hoesein, FA; Zanen, P; Lammers, JW (June 2011). "Lower limit of normal or FEV1/FVC<0.70 in diagnosing COPD: an evidence-based review". Respiratory medicine105 (6): 907–915. doi:10.1016/j.rmed.2011.01.008. PMID21295958.
^Wanger, J; Clausen, JL; Coates, A; Pedersen, OF; Brusasco, V; Burgos, F; Casaburi, R; Crapo, R; et al. (September 2005). "Standardisation of the measurement of lung volumes". The European Respiratory Journal26 (3): 511–522. doi:10.1183/09031936.05.00035005. PMID16135736.
^ abcFauci, Anthony S.; Daniel L. Kasper; Dan L. Longo; Eugene Braunwald; Stephen L. Hauser; J. Larry Jameson (2008). Chapter 254. Chronic Obstructive Pulmonary Disease Harrison's Principles of Internal Medicine (17th ed.). New York: McGraw-Hill. ISBN978-0-07-147691-1.
^Spencer, S; Karner, C; Cates, CJ; Evans, DJ (2011). "Inhaled corticosteroids versus long acting beta(2)-agonists for chronic obstructive pulmonary disease". Cochrane Database of Systematic Reviews12 (CD007033): CD007033. doi:10.1002/14651858.CD007033.pub3. PMID22161409.
^Karner, C; Chong, J; Poole, P (21 July 2014). "Tiotropium versus placebo for chronic obstructive pulmonary disease.". The Cochrane database of systematic reviews7: CD009285. PMID25046211.
^Poole, P; Black, PN; Cates, CJ (2012). "Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease". Cochrane Database of Systematic Reviews8 (CD001287): CD001287. doi:10.1002/14651858.CD001287.pub4. PMID22895919.